ºÒ¸éÁõ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¿¹Ãø : Ä¡·á À¯Çü, ¾à¹° Á¾·ùº°, À¯Åë ä³Î, Áö¿ªº°(2025-2033³â)
Insomnia Market Size, Share, Trends and Forecast by Therapy Type, Drug Class, Distribution Channel, and Region, 2025-2033
»óǰÄÚµå : 1702264
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,154,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,539,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,925,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ºÒ¸éÁõ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 53¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö 67¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025³âºÎÅÍ 2033³â±îÁö 2.55%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, 2024³â¿¡´Â 36.4% ÀÌ»óÀÇ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Çö´ëÀÎÀÇ ¶óÀÌÇÁ½ºÅ¸Àϰú ½ºÆ®·¹½º·Î ÀÎÇÑ °Ç°­ °ü¸®¿¡ ´ëÇÑ °ü½É Áõ°¡, Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇÑ Á¤È®µµ Çâ»ó, »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ À¯·ÂÇÑ ¿¬±¸, ÀÇ·áºñ Áõ°¡, µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÇ ÅëÇÕ, Àü·«Àû ¾÷°è Á¦ÈÞ, ºñ¾à¹° ¿ä¹ý¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼±È£µµ Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ÷´Ü ÇコÄɾî, ¼ö¸é Àå¾ÖÀÇ ³ôÀº À¯º´·ü, Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ Ã¤ÅÃÀÌ ºÒ¸éÁõ ½ÃÀå Á¡À¯À²À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù.

ºÒ¸éÁõÀº ¿¡³ÊÁö ¼öÁØÀ» ³·Ãß°í °³ÀÎÀÇ ±âºÐ, °Ç°­, ¾÷¹« ¼öÇà ¹× Àü¹ÝÀûÀÎ »îÀÇ Áú¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¼ö¸é Àå¾ÖÀÔ´Ï´Ù. ÀϹÝÀûÀÎ ¿øÀÎÀ¸·Î´Â ½ºÆ®·¹½º, Àå±â ¿©Çà, ¹Ù»Û ¾÷¹« ÀÏÁ¤, ¼ö¸é ½À°ü Àå¾Ö, ÆøÀ½, Æø½Ä, ´ÏÄÚÆ¾, Ä«ÆäÀÎ, ¾ËÄÚ¿Ã °ú´Ù ¼·Ãë µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿Ü»ó ÈÄ ½ºÆ®·¹½º¿Í °°Àº Á¤½ÅÁúȯ, õ½ÄÀ̳ª Ç÷¾ÐÀ» À§ÇÑ Ç׿ì¿ïÁ¦, ÁøÅëÁ¦, ¾Ë·¹¸£±â, °¨±â¾àÀ» À§ÇÑ ÀϹÝÀǾàǰ(OTC) µîÀÇ ¾à¹°ÀÇ »ç¿ë°úµµ °ü·ÃÀÌ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÎÁöÇൿġ·á(CBT), OTC ¼ö¸é º¸Á¶Á¦, ¿¡½ºÁ¶ÇÇÅ©·ÐÀ̳ª ¶ó¸áÅ׿°ú °°Àº ó¹æ¾à µî ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀÌ ÇöÀç Àü ¼¼°èÀûÀ¸·Î Á¦°øµÇ°í ÀÖ½À´Ï´Ù.

ºÒ¸éÁõ ½ÃÀå µ¿Çâ:

Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ´ëÀ¯ÇàÀº »çȸÀû °í¸³, ¼ö¸¹Àº ¾÷¹« °úÁ¦, °¡Á· Àǹ« µî Àü·Ê ¾ø´Â »îÀÇ º¯È­¸¦ °¡Á®¿Ô½À´Ï´Ù. ÀÌ´Â ¼ö¹é¸¸ ¸íÀÇ ¼ö¸é ÆÐÅÏ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Å« ½ºÆ®·¹½º°¡ µÇ¾î ½ÃÀå ¼ºÀåÀ» °­È­Çß½À´Ï´Ù. ¶ÇÇÑ ¸¸¼º ÅëÁõ, ¾Ï, ´ç´¢º´, ½ÉÀ庴, õ½Ä, À§½Äµµ¿ª·ùÁúȯ(GERD), °ú¹Î¼º °©»ó¼±, ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´°ú °°Àº Áúº´Àº ÀϹÝÀûÀ¸·Î ºÒ¸éÁõ°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Áúº´À» ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ Áõ°¡´Â ºÒ¸éÁõ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î, »ý¸®ÁÖ±â ¹× Æó°æ±âÀÇ È£¸£¸ó º¯È­´Â ºÒ¸éÁõ ¹ßº´ÀÇ À§ÇèÀ¸·Î À̾îÁú ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö¸é ÆÐÅÏ, Ȱµ¿, °Ç°­ÀÇ º¯È­ ¹× 󹿾àÀÇ »ç¿ë Áõ°¡·Î ÀÎÇØ ³ëÀÎÀÇ ºÒ¸éÁõ °¡´É¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àü ¼¼°è ³ëÀÎ Àα¸ÀÇ Áõ°¡´Â ºÒ¸éÁõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀÚ±ØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÒ¸éÁõ ¿¹¹æ, Áø´Ü, Ä¡·á ¹× °ü¸®¸¦ À§ÇÑ »õ·Î¿î Ä¡·á, ÁßÀç ¹× °Ë»ç ½ÃÇè¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡°¡ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ºÒ¸éÁõ ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : Ä¡·á À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : ¾à¹° Á¾·ùº°

Á¦8Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global insomnia market size was valued at USD 5.34 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 6.78 Billion by 2033, exhibiting a CAGR of 2.55% during 2025-2033. North America currently dominates the market, holding a significant market share of over 36.4% in 2024. Increasing prevalence due to modern lifestyles and stress, advancements in diagnostic technologies enhancing accuracy, robust research into novel therapies, rising healthcare expenditures, integration of digital health solutions, strategic industry collaborations, and growing consumer preference for non-pharmacological treatments are some of the factors bolstering the market growth. In addition to this, advanced healthcare, high sleep disorder prevalence, and adoption of innovative treatments are further increasing the insomnia market share.

Insomnia is a sleep disorder that can lower energy levels and affect the mood, health, work performance, and overall life quality of an individual. Its common causes include stress, long travels, hectic work schedules, poor sleep habits, binge eating, and excessive consumption of nicotine, caffeine, and alcohol. It can also be associated with mental health disorders, such as post-traumatic stress, and the use of drugs like antidepressants for asthma or blood pressure and over-the-counter (OTC) for pain relief, allergy, and cold. Its treatment options, such as cognitive-behavioral therapy (CBT), OTC sleep aids, and prescription medications like Eszopiclone and Ramelteon, are currently available worldwide.

Insomnia Market Trends:

The coronavirus disease (COVID-19) pandemic generated unprecedented changes in lives, including social isolation and innumerable work challenges and family obligations. This acts as a major stressful event that impacted the sleep patterns of millions and strengthened the market growth. Moreover, medical conditions, such as chronic pain, cancer, diabetes, heart disease, asthma, gastroesophageal reflux disease (GERD), overactive thyroid, Parkinson's disease, and Alzheimer's disease, are usually linked with insomnia. Hence, the increasing number of individuals suffering from these ailments is driving the demand for insomnia medications. Apart from this, hormonal shifts during the menstrual cycle and menopause can lead to the risk of developing insomnia, which is contributing to the market growth. In addition, as changes in sleep patterns, activity, and health and the rising use of prescription drugs can increase the chance of insomnia among older people, the growing geriatric population globally is catalyzing the demand for insomnia medical treatment. Furthermore, increasing investments in testing new treatments, interventions, and tests to prevent, detect, treat, and manage insomnia are anticipated to drive the market.

Key Market Segmentation:

Breakup by Therapy Type:

Breakup by Drug Class:

Breakup by Distribution Channel:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Aurobindo Pharma Limited, Biocodex, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Merck & Co. Inc., Neurim Pharmaceuticals Inc., Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo Chemical Co. Ltd.), Takeda Pharmaceutical Company Limited and Vanda Pharmaceuticals Inc.

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Insomnia Market

6 Market Breakup by Therapy Type

7 Market Breakup by Drug Class

8 Market Breakup by Distribution Channel

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â